Regeneron faces securities lawsuit after melanoma trial triggers $11 billion market-cap loss
AI Summary- Hagens Berman filed a securities class action concerning Regeneron’s melanoma trial disclosures.
- $11 billion in market capitalization was erased after the trial failure was reported.
- Investors covered the case period from Aug. 1, 2025, through May 15, 2026.